Teriparatide is a recombinant peptide commercialized by Entera Bio, with a leading Phase II program in Hypoparathyroidism. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Teriparatide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Teriparatide is expected to reach an annual total of $26 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Teriparatide Overview

EB-612 is under development for the treatment of hypoparathyroidism. The drug candidate is administered orally in the form of tablet. PTH (1-34) is a regulator of calcium levels in the blood. The drug candidate is developed based on technology that works by protecting and stabilizing orally active peptides from the harsh chemical environment of stomach while in passage through the gastrointestinal tract thereby promoting their absorption.

Entera Bio Overview

Entera Bio is a biopharmaceutical company that specializes in the oral delivery of molecules and biologics. The company develops novel drug delivery platforms for oral delivery of large molecule protein active pharmaceutical ingredients. It offers product candidates such as EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Its other pipeline products include GLP-2 for short bowel syndrome and hGH for GH deficiency. Entera Bio conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal tract. The company also provides treatment for bone healing. It operates in Israel and the US. Entera Bio is headquartered in Jerusalem, Israel.

The company reported revenues of (US Dollars) US$0.6 million for the fiscal year ended December 2021 (FY2021), an increase of 56.4% over FY2020. The operating loss of the company was US$12.2 million in FY2021, compared to an operating loss of US$11.2 million in FY2020. The net loss of the company was US$12.2 million in FY2021, compared to a net loss of US$11.2 million in FY2020.

For a complete picture of Teriparatide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.